Introduction
Metabolomics
Prediction of mortality in community-acquired pneumonia
Prediction of mortality in patients hospitalized with exacerbated chronic obstructive pulmonary disease
Aims of the review and methodology
Promising metabolic biomarkers for prediction of all-cause mortality
Steroid hormones
Pathway and physiological role
Current research (Table 1)
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Mueller et al., 2014, [53] | - Cortisol | Single-center, prospective observational cohort study (6-week follow-up)/secondary chart analysis of a single-center, randomized controlled interventional study | 179 prospectively recruited patients hospitalized with CAP | - In age and gender adjusted logistic regression analysis, cortisol (OR: 2.8; 95 % CI: 1.48–5.28, p = 0.002) and DHEA (OR: 2.62; 95 % CI: 1.28–5.34, p = 0.008), but not DHEA-S and none of the different ratios (cortisol/DHEA, cortisol/DHEA-s, DHEA/DHEA-S) were associated with increased 6-week all-cause mortality; the discriminatory accuracy in ROC analysis (AUC) to predict mortality was 0.74 (95 % CI: 0.60–0.88) for cortisol, 0.61 (95 % CI: 0.46–0.75) for DHEA and 0.72 (95 % CI: 0.62–0.81) for the PSI | - Single-center study |
- DHEA | - Secondary chart analysis of remaining blood samples; the study had not been prospectively designed to use adrenal hormone concentrations as a primary endpoint [139] | ||||
- DHEA-S | - Cortisol, DHEA-S and DHEA levels were measured at different times during the day | ||||
Christ-Crain et al., 2007, [59] | - Free cortisol | Single-center, prospective observational cohort study (6.9 +/− 1.9-week follow-up)/secondary chart analysis of a single-center, randomized controlled interventional study | 278 prospectively recruited patients presenting to the emergency department with CAP | - Initial TC and FC levels were significantly higher in non-survivors than in survivors (p < 0.001 for TC and p = 0.004 for FC); the area under the receiver operating characteristic curve (AUC) to predict death was 0.76 (95 % CI, 0.70–0.81) for TC and 0.69 (95 % CI, 0.63–0.74) for FC, whereas the AUC of the PSI was 0.76 (95 % CI, 0.70–0.81) to predict mortality | - This study had not been prospectively designed to use cortisol concentrations as a primary endpoint, and only single initial cortisol levels were measured [139] |
- Total cortisol | - The prognostic accuracy of FC was not higher than the one for TC (p = 0.12) | - Cortisol levels were measured at different timepoints during the day | |||
- No assessment of adrenal function | |||||
- TC and FC levels were independent mortality predictors in pneumonia; the prognostic accuracy of total cortisol equaled the predictive power of the PSI | |||||
Kolditz et al., 2012, [60] | Cortisol | Multicenter, prospective observational cohort study (patients recruited from CAPNETZ) (30-day follow-up) | 984 hospitalized CAP patients, recruited from a multicenter national CAP-study in Germany | - After a follow-up period of 30 days initial serum cortisol levels were significantly higher in non-survivors than in survivors (p < 0.001); the AUC to predict 30-day mortality was 0.70 (cut-off serum cortisol value 795 nmol/l) | - No correction for concomitant steroid medication, due to absent data |
- Predictive accuracy of the CURB-65 score alone (AUC 0.76) was significantly improved by combining with serum cortisol levels (AUC 0.81, p = 0.001) | - Since blood samples were taken at time of first contact, cortisol levels were measured at different time points during the day; however, during infectious diseases and thus increased stress levels the circadian pattern of cortisol production is often lost [140] | ||||
- Survival analysis by Kaplan-Meyer curves demonstrated a significantly different survival within cortisol-quartiles (p < 0.001), which persisted within individual CURB-65 classes (p = 0.002–0.003). | |||||
- No assessment of adrenal function | |||||
Kolditz et al., 2010, [61] | - Cortisol | Single-center, prospective observational cohort study (30-day follow-up) | 59 adult patients hospitalized with CAP | - After a follow-up period of 30 days cortisol was significantly higher in non-survivors compared to survivors (p = 0.009) and was an independent predictor of short-term mortality (OR 1.002, 95 % CI 1.000–1.004, p = 0.04) | - Small sample size |
- DHEA | - The prognostic accuracy of serum cortisol (AUC 0.83 (0.62–1.0); cut-off serum cortisol: 734 nmol/l) was similar to that of the PSI (AUC 0.86 [0.75–0.97]) and superior to that of the CURB-65 score (AUC 0.68, 95 % CI 0.50–0.85) in predicting 30-day mortality | - Single-center study | |||
- DHEA-S | - No measurements of serum levels of free cortisol | ||||
- Cortisol, DHEA and DHEA-S levels were measured at different timepoints during the day, which could limit the prognostic accuracy of one single cortisol value | |||||
- Serum cortisol levels were independent 30-day mortality predictors in pneumonia, whereas DHEA and DHEA-S showed no significant difference between survivors and non-survivors (p = 0.16 and p = 0.70) | |||||
- DHEA-S shows age-dependent differences in secretion levels | |||||
Salluh et al., 2008, [62] | Total cortisol | Single-center, prospective observational cohort study (follow-up until death (in-hospital mortality) or hospital discharge) | 72 patients with severe CAP admitted to the ICU | - TC levels were significantly higher in non-survivors compared to survivors (p = 0.003 for TC), whereas postcorticotropin cortisol levels and Δ-cortisol achieved no significant difference between survivors and nonsurvivors (p ≥ 0.05, exact value not shown) | - Small sample size with a mortality rate of only 16.7 % (12 patients), leading to low statistical power |
- Increases in mortality rates were observed across all quartiles of baseline TC levels | - Single-center study | ||||
- The AUC to predict mortality was 0.77 (95 % CI, 0.64–0.90; p = 0.002; cut-off 25.7 μg/dl) for TC, 0.60 for delta-cortisol (95 % CI 0.42–0.78; p = 0.24), 0.58 for postcorticotropin cortisol (95 % CI 0.43–0.74; p = 0.33), 0.71 for CURB-65 (95 % CI 0.57–0.86; p = 0.01) and 0.71 for APACHE II score (95 % CI 0.56–0.86; p = 0.01), whereas baseline TC achieved a significantly higher AUC than postcorticotropin cortisol (p = 0.03) | - No data about patients with severe immunosuppression | ||||
- No measurement of free cortisol levels | |||||
- Kaplan-Meier curves demonstrated serum baseline cortisol (TC) concentration of >25.7 μg/dl on presentation to have a significantly higher risk of death (log rank test, p < 0.001) compared to baseline cortisol levels below this cut-off (p = 0.019) | - Measurement of cortisol levels at different timepoints during the day, potentially limiting the prognostic accuracy of one single cortisol value | ||||
- Potential confounding due to treatment with corticosteroids in the study population | |||||
- In univariate analysis, baseline cortisol, CURB-65 and APACHE II score were predictors of short-term mortality | |||||
Cortés-Puch et al., 2014, [63] | - Total cortisol | Experimental, prospective animal study (96-hour follow-up) | 101 canine suffering from S. aureus pneumonia-induced sepsis | - At 10 h after onset of sepsis total and free cortisol levels and change in cortisol levels after exogenous ACTH administration (delta cortisol) showed no significant difference between survivors and non-survivors (p = 0.75 for TC, p = 0.80 for FC, p = 0.64 for delta cortisol after ACTH stimulation), whereas ACTH levels correlated significantly, but weakly, with mortality 10 h after onset of sepsis (p = 0.04) | - Low sample size |
- Free cortisol | - Cortisol responses may partly be attributed to sedation, intubation, mechanical ventilation, and repeated ACTH stimulation testing | ||||
- At 24 h total and free cortisol, ACTH levels as well as delta cortisol after ACTH stimulation correlated significantly with | |||||
- ACTH | |||||
- Aldosterone | |||||
Ohlsson et al., 2010, [65] | - DHEA | Prospective observational population-based cohort study (mean 4.5-year follow-up) | 2644 Swedish men from the Swedish multicenter Osteoporotic Fractures in Men cohort | - Low levels of DHEA-S and DHEA (quartile 1 vs. quartiles 2–4) predicted all-cause mortality (multivariate adjusted HR 1.54, 95 % CI 1.21–1.96 for DHEA-S; HR 1.48, 95 % CI 1.17–1.88 for DHEA) | - Single measurement of DHEA and DHEA-S at different timepoints during the day with subsequent possible diurnal variation in serum DHEA and DHEA-S levels |
- DHEA-S | |||||
- Age-adjusted risk of all-cause mortality was increased in men within Q1 of DHEA and DHEA-S levels compared with men within the individual quartiles 2, 3 and 4 (Q2, Q3, Q4) (Q1: HR 1.00 (referent); DHEA: Q2 vs. Q1 HR 0.69, Q3 vs. Q1 HR 0.66, Q4 vs. Q1 HR 0.60; DHEA-S: Q2 vs. Q1 HR 0.69, Q3 vs. Q1 0.71, Q4 vs. Q1 0.60) | - No data about treatment with corticosteroids or other hormones, which might alter mortality risk and/or DHEA and DHEA-S levels | ||||
Hsu et al., 2012, [66] | DHEA-S | Single-center, prospective observational cohort study (mean follow-up time: 38.2 +/− 20.4 months) | 200 CKD patients (men) on hemodialysis (HD) more than 6 months | - Low plasma DHEA-S levels (cut-off 790 ng/ml) showed significant association with increased all-cause mortality (HR 3.667, 95 % CI 1.710–7.909; p = 0.001) in hemodialysis men, but not in women (data not shown) | - Single-center study |
- No assessmet of testosterone levels as a precursor of DHEA-S | |||||
- Multivariate Cox regression analysis adjusted for age, comorbidities such as diabetes mellitus, chronic heart failure, COPD, CRP as well as for albumin and creatinine demonstrated an independent association between low plasma DHEA-S levels and all-cause mortality in HD men (HR 2.93, 95 % CI 1.09–7.89; p = 0.033) | - Plasma DHEA-S levels were analyzed from one single pre-dialysis sample | ||||
Feng et al., 2014, [67] | - Estradiol | Single-center, prospective observational cohort study (28-day follow-up) | 107 clinically diagnosed pneumonia-related septic shock patients | - Serum levels of progesterone and estradiol were significantly higher in non-survivors compared to survivors (p < 0.001), whereas testosterone levels were similar in both groups (p = 0.74) | - Single-center study |
- Progesterone | - Most of the patients participating in the study were male | ||||
- Testosterone | - The discriminatory accuracy in ROC analysis (AUC) to predict 28-day mortality was 0.87 (p < 0.001) for the APACHE II score (cut-off 26 points), 0.705 (p < 0.001) for estradiol (cut-off 40 pg/ml), 0.713 (p < 0.001) for progesterone (cut-off 1.03 ng/ml) and 0.518 (p = 0.74) for testosterone (cut-off 4.4 ng/ml) | - No enrollment of premenopausal women | |||
- Blood sample collection for hormone measurements only on the first day of septic shock (no investigation of the dynamic of serum sex hormone levels during the course of disease) | |||||
Shores et al., 2014, [68] | - Total testosterone | Prospective observational cohort study (9-year follow-up) | 1032 men in the Cardiovascular Health Study (CHS) | - Adjusted for age and cardiovascular risk factors, low DHT (<25 ng/dl) and cFDHT (<0.13 ng/dl) levels showed significant associations with higher all-cause mortality, even if adjusted for cardiovascular risk factors (HR 1.31, 95 % CI 1.04–1.65 for DHT; HR 1.72, 95 % CI 1.25–2.37 for calculated free DHT; p < 0.001 for both) | - Only one single testosterone measurement |
- Time of day for blood collection was not standardized; however, the effects of these varying time points of blood collection might be minimal due to less circadian fluctuation in testosterone levels in older men and no significant circadian variation of DHT levels [141] | |||||
- Calculated free testosterone | - TT and cFT as well as SHBG were not significantly associated with all-cause mortality (HR 1.05 (0.88–1.25) for testosterone; HR 1.04 (0.88–1.23) for cFT) | ||||
- DHT | |||||
- Calculated free DHT | |||||
Friedrich et al., 2012, [69] | - Total testosterone | Analysis from two German prospective cohort studies (DETECT and SHIP trial) (mean follow-up of 5.5 years) | 3942 men | - Cox regression analyses adjusted for waist-to-height ratio, smoking and physical activity revealed that men with total serum testosterone levels below the 10th percentile showed an increased independent risk of all-cause mortality compared to subjects with higher hormone levels (HR 1.54, 95 % CI 1.20–1.99, p < 0.01); by additional inclusion of liver disease, increased blood pressure, diabetes and hsCRP as confounders the results were still significant for the 10th percentile as a cut-off (HR 1.38, 95 % CI 1.06–1.78, p = 0.02); using the 20th percentile as a cut-off resulted in no significant difference in all-cause morality between lower and higher testosterone levels (unadjusted model: HR 1.25, 95 % CI 0.99–1.57, p = 0.06) | - Only one single serum total testosterone measurement at baseline |
- Blood collection at different timepoints during the day; however, serum samples showed only minor differences in testosterone levels collected before and after noon; therefore the effect of the diurnal variation seems to be minimal | |||||
- In univariate Kaplan-Meier survival analysis patients with lower serum total testosterone levels (cut-off: 10th percentile) showed significantly higher all-cause mortality compared to subjects with non-low hormone levels (p < 0.01) | - Use of different assay systems to determine total testosterone | ||||
- No measurement of SHBG and thus no calculation of free testosterone levels | |||||
Grossmann et al., 2014, [70] | - Total testosterone | Single-center, prospective observational cohort study (median follow-up of 8.5-years) | 221 patients with CKD III-IV, undergoing dialysis or KTR | - Cox proportional hazards regression showed significant independant association between low total testosterone levels and high mortality rates (p = 0.01) | - Small female sample size |
- Single-center study | |||||
- DHT | - No data about patients with CKD I-II | ||||
- Estrone | - Low testosterone concentrations were independent mortality predictors in men, whereas sex steroid levels in women showed no significant association with all-cause mortality | ||||
- Estradiol | |||||
- DHEA | |||||
Araujo et al., 2007, [71] | - Total testosterone | Prospective population-based observational cohort study (secondary chart analysis of MMAS study) (15.3-year follow-up) | 1686 men aged 40 to 70 years, population-based randomly sampled | - In multivariate, age-adjusted models TT levels as well as FT, DHT and SHBG were not significantly associated with all-cause mortality | - Inclusion of mostly white men of higher socioeconomic status; thus results may not be generalizable |
- Free testosterone | - Categorizing TT, FT, DHT and SHBG into 5 quintiles yielded no significant correlation with all-cause mortality either (for TT: reference group (RR = 1): TT ≥ 650 ng/dl; < 370 ng/dl: RR 1.24 (95 % CI 0.89–1.73); 370–466 ng/dl: RR 1.00 (95 % CI 0.70–1.42); 466–545 ng/dl: RR 1.05 (95 % CI 0.74–1.47); 545–650 ng/dl: RR 1.20 (95 % CI 0.86–1.69) (p for trend = 0.50)) | - No data about women in this study | |||
- DHT | |||||
- SHBG | |||||
- Lowest quintile of free testosterone level was significantly associated with decreased IHD mortality (p for trend = 0.02) and increased respiratory disease mortality (p for trend = 0.002); | |||||
- In conclusion, TT and FT as well as DHT seem to have a relatively weak or no association with all-cause mortality | |||||
De Padua Mansur et al., 2012, [72] | Estrone | Single-center, prospective observational cohort study (5.8 +/− 1.4-year follow-up) | 251 postmenopausal women in the ambulatory care clinic of a tertiary cardiology hospital | - Kaplan Meier survival curve showed a significant association between higher all-cause mortality in women and low estrone levels (<15 pg/ml) (p = 0.039) | - Single-center study |
- No data about male patients | |||||
- Multivariate Cox regression analysis adjusted for diabetes, body mass index, dyslipidemia, and family history showed estrone to be the only independent predictor for all-cause mortality (OR 0.45 (95 % CI 0.21–0.95); p = 0.038) | - Only 32 deaths and thus relatively low statistical power |
Biogenic amines
I. L-arginine metabolites: Asymmetric dimethylarginine and symmetric dimethylarginine
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Böger et al., 2009, [77] | - ADMA | Observational, prospective cohort study (median follow-up of 10.9-year) | 3,319 middle-aged participants (Framingham Offspring Study) | - ADMA was positively associated with mortality (multivariable-adjusted HR 1.21, 95 % CI 1.07–1.37, p = 0.003) | - Only middle-aged subjects |
- L-arginine | |||||
- Arginin/ADMA-ratio was inversely associated with mortality (HR 0.80, 95 % CI 0.69–0.93, p = 0.004) | |||||
- Higher ADMA levels (p = 0.0002) and lower Arg/ADMA-ratios (p = 0.0005) were associated with elevated mortality in non-diabetic subjects | |||||
Pizzarelli et al., 2013, [78] | - ADMA | Single-center, prospective cohort study (median follow-up of 110 months) | 1,025 randomly selected adults (>65 years) living in Chianti area, Tuscany, Italy | - Plasma ADMA was a strong predictor of all-cause mortality (HR 1.26, 95 % CI 1.10–1.44, p < 0.001) and there was a non-significant trend for cardiovascular mortality (HR 1.22, p = 0.07) after multivariate adjusment | - Single-center study |
- L-arginine | - Only one ethnic population | ||||
- There was no association of ADMA with mortality in subjects with high L-arginine, but an increase in mortality in those with normal to low L-arginine | |||||
Siegerink et al., 2013, [79] | - ADMA | Multicenter, observational, prospective cohort study (median follow-up of 8.1 years) | 1,148 subjects suffering from myocardial infarction/ACS, or undergoing cardiac surgery due to CHD | - After adjustment for confounders higher levels of ADMA (HR 1.15, 95 % CI 0.95–1.37) and SDMA (HR 1.29, 95 % CI 1.09–1.52) were associated with an increase in all-cause mortality | - Selection bias |
- SDMA | - Only two-center study | ||||
(KAROLA Study, Germany) | |||||
Koch et al., 2013, [80] | ADMA | Single-center, observational prospective cohort study (3-year follow-up) | 255 ICU patients and 78 healthy controls living in Germany | - ICU patients had higher serum ADMA levels than healthy controls (median 0.48 vs. 0.36 μmol/L, p < 0.001) | - Short-term intensive care (<72 h) patients were excluded |
- ICU non-survivors had higher ADMA levels compared with ICU survivors (median 0.62 vs. 0.44 μmol/L, p < 0.001) | - Single-center study | ||||
- High ADMA levels predicted all-cause mortality in critically ill patients (p < 0.001) | |||||
- ADMA levels increased during 7 days of ICU therapy (p < 0.001) | |||||
Koch et al., 2013, [81] | SDMA | Single-center, observational prospective cohort study | 247 ICU patients and 84 healthy controls living in Germany | - ICU patients had higher serum SDMA levels than healthy controls (median 0.84 vs. 0.38 μmol/L, p < 0.001) | - Short-term intensive care (<72 h) excluded |
- ICU non-survivors had higher SDMA levels compared with ICU survivors (median 1.33 vs. 0.74 μmol/L, p = 0.001) | - Single-center study | ||||
(3-year follow-up) | - High SDMA levels predicted poorer long-term prognosis in critically ill patients (p < 0.001) | ||||
Gore et al., 2013, [82] | - SDMA | Observational prospective cohort study (median follow-up of 7.4 years) | 3,523 adults aged 30 to 65 years (Dallas Heart Study) | - After adjustment for cardiorenal indices, age, sex, race, NT-proBNP, hsCRP and Troponin, SDMA, but not ADMA, was associated with all-cause mortality (HR 1.86, 95 % CI 1.04–3.30, p = 0.01) | - Single blood sampling |
- ADMA | |||||
Suzuki et al., 2011, [85] | - Kynurenine | Single-center, observational prospective cohort study | 129 Japanese patients with CAP and 64 healthy controls | - CAP patients had elevated levels of Kyn (p < 0.0001) and reduced levels of Trp (p < 0.0001) compared with healthy controls and thus higher Kyn/Trp ratios (p < 0.0001) | - Single-center study |
- Tryptophan | - Small sample size | ||||
- No information about duration of follow-up | |||||
- Increasing severity of sepsis and CAP (PSI and CURB-65 score) was associated with higher Kyn levels, lower Trp levels and higher Kyn/Trp ratios. | |||||
- Non-survivors had higher Kyn levels (p = 0.023) and lower Trp levels (p = 0.032) and as a result, higher Kyn/Trp ratios (p = 0.005) | |||||
Darcy et al., 2011, [86] | - Kynurenine | Single-center, observational prospective cohort study | 50 patients from Australia with severe sepsis (organ dysfunction or shock), 30 with non-severe sepsis and 40 hospital controls | - Sepsis patients had elevated levels of Kyn (p < 0.0001) and reduced levels of Trp (p < 0.0001) and thus higher Kyn/Trp ratios (p < 0.0001) compared with hospital controls. | - Single-center study |
- Tryptophan | - Small sample size | ||||
- Kyn/Trp ratio was increased in severe sepsis compared with non-severe sepsis (p = 0.0006) | |||||
(28-day follow-up) | |||||
- Kyn/Trp ratio did not differ between survivors and non-survivors by day 28 of the study (p = 0.2) | |||||
Huttunen et al., 2010, [87] | - Kynurenine | Single-center, observational prospective cohort study (30-day follow-up) | 132 patients with bacteremia admitted to Tampere University Hospital in Finland | - Maximum Kyn/Trp ratios were significantly elevated in non-survivors (30-day case fatality) compared with survivors (193.7 vs. 82.4 μmol/mmol; p < 0.001) | - Small sample size |
- Tryptophan | - Single-center study | ||||
Qian et al., 2013, [92] | 3-nitrotyrosine | Single-center, observational prospective cohort study (90-day follow-up) | 158 patients with AKI, 12 critically ill patients without AKI, 15 healthy controls | - Patients with AKI had higher 3-NT/Tyr levels than healthy and critically ill controls (p < 0.001) | - Relatively small size study |
- Single-center study | |||||
- High 3-NT/Tyr was associated with higher 90-day mortality (p = 0.025) |
II. Kynurenine
III. Nitrotyrosine
Trimethylamine-N-oxide, betaine, choline
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Tang et al.., 2015, [102] | TMAO | Single-center, prospective observational cohort-study (5-year follow-up) | 112 adults with stable but symptomatic chronic systolic HF (left ventricular ejection fraction ≤35 %) (Cleveland Clinic) | - After adjustment for age, eGFR, and NT-proBNP levels, higher TMAO levels were associated with poor prognosis (death/transplantation) (HR 1.46; 95 % CI 1.03-2.14; p = 0.03) | - Single-center study |
- Selection bias | |||||
- TMAO levels were higher in subjects with higher plasma NT-proBNP levels and NYHA functional class III or IV (p = 0.02) | |||||
Tang et al.,, 2013, [103] | TMAO | Single-center, prospective interventional study (9-day follow-up) | 40 healthy adults without chronic illnesses, active Infections or antibiotic therapy (Cleveland Clinic) | - Increasing plasma levels of TMAO after oral phosphatidylcholine challenge | - Small study population |
- Only healthy adults included | |||||
- In 6 adults, plasma levels of TMAO were markedly suppressed after a weekly therapy with broad-spectrum antibiotics and reappeared after withdrawal of antibiotics. | |||||
Tang et al., 2013, [103] | TMAO | Single-center, prospective observational cohort-study (3-year follow-up) | 4,007 adults undergoing elective diagnostic cardiac catheterization without evidence of an ACS (Cleveland Clinic) | - Elevated plasma levels of TMAO were associated with a higher risk of a major cardiovascular event after adjustment for traditional risk factors (p < 0.001) | - Single-center study |
- Selection bias | |||||
- Prognostic value of elevated plasma levels of TMAO remained significant in low-risk subgroups | |||||
Tang et al.., 2014, [101] | TMAO | Single-center, prospective observational cohort study (5-year follow-up) | 720 subjects with a history of HF (Cleveland Clinic) | - Subjects with HF (5.0 μmol) had higher median TMAO levels than subjects without HF (3.5 μmol; p < 0.001) | - Single-center study |
- Selection bias | |||||
- TMAO levels were predictive of 5-year mortality risk after adjustments for traditional risk factors, BNP levels and eGFR (HR 1.75; 95 % CI 1.07–2.86; p < 0.001) | |||||
Tang et al.., 2015, [100] | TMAO | Single-center, prospective observational cohort-study (5-year follow-up) | 521 subjects with CKD (eGFR < 60 mL/min) and 3,166 non-CKD subjects (Cleveland Clinic) | - TMAO levels were increased in CKD subjects (median, 7.9 μmol/L) compared with non-CKD subjects (median, 3.4 μmol/L), p < 0.001 | - No specific results for CKD stage 1-2 |
- Single-center study | |||||
- Higher TMAO levels (quartiles 4 versus 1) were associated with an increase in 5-year all-cause mortality in CKD subjects (HR 1.93; 95 % CI 1.13–3.29; p < 0.05) and non-CKD subjects after adjustment for traditional CVD risk factors and eGFR (HR 1.47; 95 % CI 1.02–3.29; p < 0.05) |
Intermediate energy metabolism
Lactate
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Ramakrishna et al., 2012, [107] | Lactate | Single-center, observational prospective cohort-study (follow-up until hospital discharge) | 233 Malawian children with pneumonia | - The odds ratio for in-hospital mortality (25 deaths) in children with lactate >2 mmol/L was 7.48 (95 % CI 1.72–32.6) compared with children with lactate <2 mmol/L | - Single-center study |
- Low statistical power (only 25 deaths) | |||||
Chen et al., 2015, [108] | Lactate | Single-center, observational prospective cohort-study (28-day follow-up) | 1,641 patients with pneumonia (861 inpatients, 780 outpatients) (Emergency Department of Beijing Chao-Yang Hospital) | - Non-survivors had higher lactate and CURB-65 scores compared with survivors (p < 0.001) | - Single-center study |
- No information about microorganisms | |||||
- Lactate predicted 28-day mortality better than CURB-65 score (AUC 0.823 vs. 0.692; p < 0.01) | |||||
- Combination of lactate and CURB-65 score improved the predictive value of CURB-65 score alone (AUC 0.851) |
Monosaccharides
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Foltran et al., 2013, [112] | Glucose | Single-center, retrospective case-control study | 1,018 Italian non-intensive care patients with pneumonia | - Plasma glucose levels of mean 86 mg/dl (95 % CI, 61–102 mg/dl) were associated with minimal risk of in-hospital mortality | - Only admission glucose levels |
- Single-center study | |||||
- No information on important confounders (e.g. diabetes) | |||||
- The OR was 1.33 (95 % CI 1.07–1.66) for each 10 mg/dl of increase in plasma glucose in hyperglycemic patients (>86 mg/dl) | |||||
McAlister et al., 2005, [113] | Glucose | Multicenter, observational prospective cohort study (median length of in-hospital stay was 6 days, follow-up until hospital discharge) | 2,471 Canadian adults with CAP | - Patients with an admission glucose level >11 mmol/l had an increased risk of death (13 vs. 9 %, p = 0.03) and in-hospital complications (29 vs. 22 %, p = 0.01) compared to those with glucose levels <11 mmol/l | - Glucose only measured once |
- No examination of antiglycemic treatments | |||||
- Not measured long-term glucose (HbA1c) | |||||
- Patients with admission glucose >11 mmol/l had 73 % higher mortality (95 % CI 12–108 %) and a 52 % higher (12–108 %) risk of in-hospital complications compared to patients with glucose levels ≤6.1 mmol/l | |||||
Lepper et al., 2012, [114] | Glucose | Multicenter, prospective cohort study (6-month follow-up) | 6,891 German patients with CAP (CAPNETZ Study) | - In patients with no pre-existing diabetes an increased serum glucose level was a predictor of death at 28 and 90 days | - Treatment of pneumonia was left to the discretion of the doctor |
- Mild hyperglycemia (6-10.99 mmol/l) on admission was associated with an increased risk of death at 90 days (HR 1.56, 95 % CI 1.22–2.01, p < 0.001), and this risk increased to 2.37 (95 % CI, 1.62–3.46, p < 0.001) when serum glucose levels were ≥14 mmol/l | - Did not examine changes in serum glucose | ||||
- Glucocorticoid treatments were not recorded | |||||
- No HbA1c tests |
Oxidative status
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Rodas et al., 2012, [118] | - Total glutathione | Single-center, prospective observational cohort study (6-month follow-up) | 174 patients admitted to the ICU (without thoracic, neurosurgery and trauma cases) (>17 years of age) | - After division of patients into quartiles according to total concentration of glutathione and GSH in whole blood, no relationship to mortality was observed (data not shown); division of patients into quartiles according to GSH/total glutathione ratio showed a significant higher 6-month-all-cause mortality for the quartile with the highest ratio compared to the lower three quartiles (p = 0.026); the AUC of GSH/total glutathione ratio regarding all-cause mortality prediction was 0.56 (p = 0.18) with an optimal cut-off for the GSH/total glutathione ratio of 0.66; a stepwise multiple logistic regression analysis regarding 6-month-mortality prediction showed an OR of 2.35 (CI 1.02-5.41; p < 0.001) for the GSH/total glutathione ratio | - The study only represented the group actually studied, namely patients >17 years of age admitted to the ICU |
- GSH | |||||
- Glutathione redox status (GSH/total glutathione ratio) | - Observational studies allow no statement about causal association | ||||
- Redox status of glutathione in plasma might not be representative for the intracellular status (Nevertheless, the plasma ratio of GSH/total glutathione could be useful as a biomarker to predict post-ICU mortality) | |||||
Herzenberg et al., 1997, [123] | - Total glutathione | Single-center, prospective observational cohort-study (2-3-year follow-up) | 204 HIV-infected patients, who were screened for enrollment into a clinical trial designed to determine whether orally NAC replenishes GSH in subjects with low GSH levels; however, subjects who were finally enrolled in the NAC trial were not included in the present observational cohort study | - Logistic regression analyses demonstrated an association between increased baseline GSB and improved 2-3-year survival, whereas baseline GSB levels below normal values showed a higher mortality (p < 0.0001) | - Selection bias due to exclusion of patients who finally were trial subjects of the NAC interventional trial |
- GSH | |||||
- GSB | |||||
- No data about plasma glutathione | |||||
- Kaplan-Meier survival curves demonstrated that patients with baseline GSB levels below 1.05 show a significantly increased 2-3-year all-cause mortality compared to subjects with higher baseline GSB levels (p = 0.005); the above named optimal treshold of 1.05 for separating survivors from non-survivors was determined using ROC analyses for 2-3-year survival | |||||
- In proportional hazard analyses with inclusion of GSB levels as well as CD4 T cell counts in the model, GSB has still been demonstrated to be a significant, independent mortality predictor (RR 1.6 [95 % CI 1.1–2.5], p = 0.009), despite its significant correlation with CD4 T cell counts (p < 0.0001) | |||||
Xiu et al., 2012, [124] | Homocysteine | Prospective observational cohort-study (up to 10-year follow-up) | 1,412 elderly >65 years of age, selected from the Elderly Nutrition and Health Survey in Taiwan (NAHSIT) [142] | - In a model adjusted for sociodemographic, behavioral, and nutritional variables, plasma homocysteine levels >14.5 umol/l were associated with significantly higher mortality compared to those <9.3 umol/l (HR 1.8, 95 % CI 1.20–2.71; p = 0.002) | - Although adjustment for several known associations with homocysteine status has been undertaken, residual confounding is still possible |
Wong et al. 2013, [125] | Homocysteine | Prospective observational population-based cohort study (follow-up of 5.1 +/− 1.3 years) | 4,248 community-dwelling Australian men aged 70–88 years, selected from the Health in Men Study (HIMS) [143] | - After adjustment for frailty, age, education, living circumstances, smoking, cardiovascular disease, cardiovascular risk factors and renal function, high total plasma homocysteine levels (≥15 umol/l) were a significant all-cause mortality predictor (HR 1.25, 95 % CI 1.06–1.48, p < 0.05) | - Self-selection of study participants might have biased the findings toward lower homocysteine, lower age and fewer comorbidities compared to the non-respondents, which limits generalizability of study results and might have moved the results toward the null hypothesis with underestimation of associations |
Swart et al., 2011, [126] | Homocysteine | Sub-study of a prospective observational population-based cohort study (11-year follow-up) | 1,117 independently living elderly (mean age = 75.1 years), selected from the Longitudinal Aging Study Amsterdam (LASA) | - After adjustment for several confounders, women in the third and the fourth quartile of plasma homocysteine levels were associated with a significantly higher all-cause mortality risk compared to those in the first quartile (Q3 HR 1.70, 95 % CI 1.08–2.65; Q4 HR 1.91, 95 % CI 1.22–3.00), independently of vitamin B12 status; in men there was no significant difference in all-cause mortality rates between different quartiles of homocysteine levels in adjusted models | - Possible underestimation of the actual relationship between homocysteine levels and mortality due to selection bias, since excluded subjects were older, more likely to be cognitively impared, less physically active and had suffered CVD more often at baseline |
Drewes et al., 2014, [127] | Homocysteine | Post-hoc subanalysis of the double-blind, randomized placebo-controlled study, stratified by plasma homocysteine levels (mean follow-up of 3.2 years) | 3,522 subjects with history of or risk factors for CVD (aged 70–82), selected from the primary care setting in two of the three PROSPER study sites (Netherlands and Scotland) | - In the placebo group subjects with plasma homocysteine levels in the highest tertile showed a significantly higher all-cause mortality risk (HR 1.7, 95 % CI 1.2–2.5, p = 0.003) as well as a greater risk of fatal and nonfatal CHD (HR 1.8, 95 % CI 1.2–2.5, p = 0.001) compared to those with low plasma homocysteine levels | - Study not originally designed to collect blood samples for plasma homocysteine level assessment, which is why data could only be used from two of the three PROSPER study sites |
- Some blood samples have possibly been stored at room temperature for up to 8 h, which could have contributed to artificially high plasma homocysteine levels, and thus misclassification | |||||
- Regarding all-cause mortality the pravastatin treatment group showed an absolute risk reduction of 4.6 % (95 % CI 0.78–8.4 %) in the subgroup with high homocysteine levels compared to -0.66 % (95 % CI -4.0–2.7) in the subgroup with low homocysteine levels (absolute risk reduction difference of 5.2 %, 95 % CI 0.19–10.3; p = 0.04) | |||||
- No data about the intakte of vitamin B, which may lower homocysteine levels | |||||
Waskiewicz et al., 2012, [128] | Homocysteine | Prospective observational, population-based cohort study (mean follow-up of 5.4 years) | 7,165 Polish people aged 20–74 years | - In multivariable proportional hazards models adjusted for sex, age and cardiovascular risk factors, RR of all-cause long-term mortality was significantly higher in plasma homocysteine levels >10.51 umol/l compared to those <8.20 umol/l (HR 1.766, 95 % CI 1.197–2.605) | - The immunoenzymatic method used to determine homocysteine levels in this study has shown the lowest precision of measurements in comparative analyses of various homocysteine assay methods |
- In Kaplan-Meier survival curves patients with homocysteine concentrations in the highest tercile (>10.51 umol/l) showed significantly increased long-term all-cause mortality compared to subjects with homocysteine levels in the lowest tercile (p = 0.0003) | - Impossible to perform analyses of mortality related to stroke and ischemic heart disease due to low number of deaths in these groups | ||||
Naess et al., 2013, [129] | Homocysteine | Prospective, observational population-based cohort study (mean follow-up of 12.4 years) | 198 patients with first ischemic stroke living in Hordaland County (mean age of 47.8 years) | - After adjustment for age, sex and CRP levels, Cox regression analysis – excluding patients with stroke caused by dissection – showed high plasma homocysteine levels (>9 ug/l) to be significantly and independently associated with all-cause mortality (HR 1.04, p = 0.02) | - Small sample size |
- Possible selection bias due to retrospective patient recruitment | |||||
- High plasma homocysteine levels have been shown to be significant all-cause mortality predictors only after exclusion of patients with dissection, suggesting homocysteine to be a potential confounder in mortality prediction | |||||
Vieira et al., 2010, [130] | Homocysteine | Single-center, prospective observational cohort-study (2-year follow-up) | 95 predialysis patients with chronic kidney disease (mean age of 69.4 years) | - Kaplan-Meier survival curves demonstrated a significant lower survival in patients with total plasma homocysteine levels and nutritional status assessment (by mSGA) above the mean level compared to lower levels (p = 0.04; survival at 24 months = 50 %) | - Small sample size |
Tekin et al., 2012, [144] | Homocysteine | Single-center, prospective observational cohort-study (1-year follow-up) | 70 patients with HF (left ventricle ejection fractions < 35 %) (mean age 60 +/− 12) | - Serum homocysteine levels were significantly higher in non-survivors compared with survivors (20.8 +/− 5.8 vs. 16.9 +/− 5.1 umol/l, p = 0.029) | - Small sample size |
- With an optimal cut-off value of >17.45 umol/l, the AUC of serum homocysteine levels with regard to mid-term mortality prediction was 0.855 (95 % CI 0.792–0.965, p < 0.001) |
Glycerophospholipids
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Sigruener et al., 2014, [132] | - Sphingomyelin | Single-center, prospective observational cohort-study (median follow-up of 8 year) | 2583 CAD-positve patients and 733 controls (LURIC Study) | - 9 PC species (PC 30:0, 30:1, 32:0, 32:1, 34:1, 34:2, 36:1, 38:0, 38:2) were positively associated with mortality | - Single-center study |
- Phosphatidyl-choline | - No information about time of blood sampling | ||||
- Lysophosphati-dylcholine | - PC 32:0 revealed the strongest positive association with mortality | ||||
- 10 PC species (PC 38:3–38:7, 36:4, 36:5, 40:6, 40:7) were significantly associated with a protective effect | |||||
- LysoPC 16:0, 18:0, and 18:2 were all associated with a protective effect | |||||
- The 4 SM species 16:0, 16:1, 24:1, and 24:2 showed positive association with mortality | |||||
Drobnik et al., 2003, [133] | Lysophosphatidyl-choline | Single-center, prospective observational cohort-study (30-day follow-up) | 102 patients with sepsis admitted to the University Hospital of Regensburg (Germany) and 56 healthy controls | - All 12 different lysoPC species and lysoPC-PC ratios were markedly decreased in patients with sepsis compared with healty controls | - Single-center study |
- Small patient populations | |||||
- No information about causes of sepsis | |||||
- The 4 lysoPC species, C16:0, C:18:0, C18:1, and C18:2, accounted for over 90 % of total lysoPC concentration | |||||
Schlitt et al., 2006, [135] | Sphingomyelin | Multicenter, prospective observational cohort-study (median follow-up of 6 year) | 1102 patients with CAD and 444 healthy controls | - CAD patients showed higher plasma SM levels than healthy controls (mean 51.8 vs. 44.9 mg/dl; p < 0.001) | - Only two-center study |
- No autopsy performed | |||||
- In multivariate analysis, elevated SM (>48.1 mg/dl) was related to cardiovascular death or nonfatal myocardial infarction (HR 1.8, 95 % CI 1.0–3.3, p < 0.05) in patients with ACS | |||||
Jiang et al., 2000, [136] | Sphingomyelin | Multicenter, observational case-control study | 556 patients scheduled for coronary angiography in New York | - Patients with CAD had higher plasma SM concentrations compared with non-CAD patients (median 52 vs. 44 mg/dl, p < 0.0001) | - Only two-center study |
- No prospective design | |||||
- The odds ratios for CAD patients for the third (2.83, 95 % CI 1.74–4.60, p < 0.0001) and fourth (2.59, 95 % CI 1.60–4.19, p = 0.0001) quartiles were higher than the first quartile |
First author, year, reference | Marker | Study type | Study population | Key findings | Limitations |
---|---|---|---|---|---|
Kalim et al., 2013, [138] | Oleoylcarnitine | 2 independent, observational case-control studies (ArMORR Study) | I: 100 non-survivors of 1-year HD and 100 survivors of at least 1-year HD matched for age, sex, and race | I: Oleoylcarnitine showed the strongest association with cardiovascular mortality after multivariable adjustment (OR ratio per SD 2.3, 95 % CI 1.4–3.8, p = 0.001) | - Measurement of basline metabolites after starting hemodialysis |
- Accuracy of ICD-9 codes for cardiac diagnoses not completely sensitive or specific | |||||
II: Oleoylcarnitine was associated with cardiovascular death (OR per SD 1.4, 95 % CI 1.1–1.9, p = 0.008) | |||||
II: 100 non-survivors of 1-year HD and 200 survivors of at least 1 year HD |